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iiiAbstract
Assessment of the propensity of non-antiarrhythmic drugs in prolonging QT/QTc interval
is critical for the progression of compounds into clinical development. Given the
similarities in QTc response between dogs and humans, dogs are often used in pre-clinical
cardiovascular safety studies. The current regulatory guidelines are based on simple
statistical analyses of QT data, thereby ignoring any potential exposure-eect relationship
and nonlinearity in the underlying physiological 
uctuation in QT values. The objective
of this analysis is to adopt a model based approach to assess the QT-prolonging eects in
dogs and humans of GSK945237, a new compound under development. Pharmacokinetic
and pharmacodynamic data from experiments in conscious dogs and clinical trials
following administration of GSK945237 were used. First, pharmacokinetic modelling was
applied to derive drug concentrations at the time of each QT measurement. A Bayesian
PKPD model was then used to describe QT prolongation, which allows discrimination of
drug-specic eects from other physiological factors known to alter QT interval duration.
Results from this analysis show the drug under investigation is not prone to cause
hazardous increases in the QT interval for both humans and dogs. Further, the PKPD
model is capable to predict both preclinical and clincal data, suggesting it might be used
for future translational research in the eld of QT prolongation.Chapter 1
Introduction
1.1 Physiolgy of the QT Interval and the Drug Eect on it
The QT interval is the portion of the Electrocardiographic signal (ECG) in between the
beginning of the QRS complex and the end of the T-wave (Figure 1.1). It represents the
time between the onset of electrical depolarization of the ventricles and the end of their
repolarization, that is, it re
ects the duration of individual action potentials in the cardiac
myocytes.
QT interval is aected by several sources of variability of diverse nature. As one would
excpect, the QT interval duration is strictly related to the RR interval (i.e. the cardiac
period). In fact it is well known that in order to improve the detections of threatening QT
prolongations, the measured QT has to be corrected for changes in RR interval, taking the
name of corrected QT interval (QTc). Other subject-related factors potentially aecting
the QT/QTc interval are:
1. Genetic (long QT syndrome)
2. Food intake
3. Circadian rhythm
4. Sex
5. Obesity
6. Physical activity
7. Blood glucose level
8. Blood pressure
9. Age
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Figure 1.1: Schematic ECG trace showing the dierent waves and intervals that charac-
terize it.
In cardiovascular safety assessment studies, considerable attention has been paid due
to the fact that both antyarrhythmic and non-antyarrhythmic drugs may prolong the QT
interval.
QT prolonging compounds do that by blocking the so-called human Ether- a-go-go Related
Gene (hERG), a gene coding for the alpha subunit of a potassium ion channel (also called,
with a bit of ambiguity, hERG) which modulates the repolarizing current IKr in the cardiac
action potential.
A possibile explanation for such drug eect has been given by Milnes et al. [1]. Starting
from the hypothesis that the high-anity drug-binding sites are within the vestibule of the
channel, they state that the absence of highly conserved prolines (normally present in K+
channels) at hERG ammino-acid positions may suggest that a \kink" is absent, thereby
more space is available within the vestibule. A potential eect of this increasing in space
inside the vestibule of the hERG would be the ability of a wide variety of drugs to gain
access to binding sites inside the pore.
The blockade of hERG channel implies a lower conductivity of K+ ions (i.e. a lower IKr),
whom re
ects on a bigger duration of the action potential of cardiac myocytes, ending with
a slower ventricular repolarization and a longer QT interval (Figure 1.2).
1.2 Motivation
Non clinical and clinical cardiovascular toxicities are one of the main safety reasons for
(i) drug discontinuation throughout all stages of drug discovery and development;1.2. MOTIVATION 3
Figure 1.2: hERG blockade proccess.
(ii) serious adverse events and adverse drug reactions during clinical development and
(iii) post marketing drug withdrawal.
Among those, prolongation of the QT/QTc interval had been the reason for one-third of
all drug withdrawals for the period 1990-2006 [2].
Although drug-induced lengthening of the QT/QTc interval is not a safety concern in itself,
this eect has been associated with the occurrence of a rare, life-threatening ventricular
tachycardia named Torsades de Pointes (TdP) [3]. Therefore the ability to assess QT/QTc
prolongation eects as early as possible during the course of the clinical development of
a new compound is helpful not only in understanding the potential risk-benet ratio of
the molecule but also in deciding whether to progress with the development of the drug,
thereby avoiding unnecessary costs.
According to the most current regulatory guideline - the International Conference of Har-
monisation (ICH) E14 Document [4] - the critical threshold for cardiovascular safety con-
cerns in the QTc-interval increasing is equal to 10 msec. Therefore, in the context of QTc
prolongation, the application of translational methods makes possible the prediction of
QTc lenghtening in humans starting from outcomes obtainend in preclinical studies; with
regard to this, the work that has been proposed provides a tool to investigate such trans-
lation and to identify the gap between preclinical and clinical ndings. Further, given that
the protocol suggested by the ICH E14 can lead to biased results for several reasons [5], in
order to increase the reliability of potential conclusions the QT interval has been described
by means of nonlinear mixed-eects modeling techniques applied in a bayesian framework.
Non linear mixed-eect modeling helps to overcome issuses due to managing sparse data4 CHAPTER 1. INTRODUCTION
coming from dierent individuals (which is the case for QT measurements in humans),
while a bayesian approach ts naturally into decision analysis since it allows to obtain the
full posterior probability plus the credible intervals of a parameter of interest instead of
a puntual estimate with its condence interval. These two aspects will be treated widely
later (see 1.3 and 1.4).
1.3 Basics of Non Linear Mixed Eect Methods
Non Linear Mixed Eect (NLME) models, also called hirerchical models, are used in pop-
ulation analysis related elds such as environmental health, agriculture and pharmacoki-
netics/pharmacodynamics.
Population analysis is an alternative method to individual analysis that has its strength
in extrapolating information from sparse data coming from dierent individuals, assuming
that each individual feature comes from a distribution of that feature which is representa-
tive of the entire population of interest.
The mathematical formulation of the model will be presented (1.3.1), followed by an applied
pharmacokinetic example (1.3.2).
1.3.1 The Basic Model
NLME modelling is more complex than standard modelling techniques, and has to be
stratied into two hirerchical steps.
1. Stage 1: Individual-Level model
The individual step aims to dene the measure model:
￿ zi;j: the jth measure (j = 1;:::;N) for the ith subject (i = 1;:::;K), collected at
time ti;j
￿ ui: vector of additional conditions under which subject i is observed
￿ pi: vector of model parameters specic to subject i (M  1)
￿ f(ti;j;ui;pi): non-linear relationship between zi;j and (ti;j;ui;pi)
￿ i;j: random error due to uncertainty in the measure denoting within-individual
variabilty
If we consider an additive residual error, the individual model can be written as
zi;j = f(ti;j;ui;pi) + i;j: (1.1)1.3. BASICS OF NON LINEAR MIXED EFFECT METHODS 5
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it is possible to summurize equation (1.1) as
zi = fi(pi) + i (1.2)
where a classical assumption on i is
ijpi s MVN(0;Ri(pi;))
with  costant accros individuals. For example it might need to incorporate a pro-
portional error model, therefore  will be constant (= 2) and Ri will be
Ri = 2fi(pi) = 2
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2. Stage 2: Population-Level model
To account for inter-individual variation of parameters pi among individuals, a model
for pi has to be specied. The population step provides this model:
￿ ai: vector of characteristics of subject i (named covariates)
￿ i: vector of random eects for subject i conveying inter-individual variation
￿ : vector of xed eects expressing features common to the entire population
￿ d: M-dimensional vector function
Then a general model for pi is given by
pi = d(ai;i;)
where a classical assumption on i is
i s MVN(0;
) (1.3)6 CHAPTER 1. INTRODUCTION
1.3.2 Pharmacokinetic Application of a NLME Model
Pharmacokinetics is the study of the time course of drug concentration in dierent body
spaces such as plasma, blood, urine, cerebrospinal 
uid, and tissues, and aims to describe
the dierent phases encountered by the compound once in the body: absorption, distri-
bution, metabolism and elimination. The representation of the body is approximated by
simple compartment models, each describing one body spaces, with the kinetics of the drug
described by dierential equations.
Suppose data from N = 6 subjects is available with the drug given orally. Figure 1.3
shows the concetration-time proles of the dierent individuals: it can be seen the sim-
iliraty in shapes across subjects, but peaks, rises, decays vary considerably. This eect
is attributable to inter-subject variation in underlying PK processes. Assuming a One-
Compartment model with oral dose D (see Figure 1.4) given at time t = 0 leads to describe
concentration C(t) at time t  0 as
C(t) =
Dka
V (ka   Cl
V )
h
e  Cl
V t   e kat
i
where
￿ ka: fractional rate of absorption [1=Hr] of the drug from the gut compartment
￿ Cl: clearence rate [ml=Hr], i.e. the volume of plasma which per unit of time is totally
cleared of a substance (e.g. a drug) by the various elimination processes (metabolism
and excretion)
￿ V : volume of distribution [ml], i.e. the theoretical volume that a drug would have
to occupy (if it was uniformly distributed), to provide the same concentration as it
currently is in blood plasma
summarize the PK processes underlying the observed concentration prole of a given sub-
ject.
The nal goal of a PK analysis is to determine the population mean values of (ka;Cl;V )
and how they vary between subjects, elucidating whether part of this variation is associ-
ated with subject characteristics (i.e. covariates, such as weight, age, renal function), in
order to develop dosing strategies for subpopulations with certain characteristics (elderly,
pediatric, etc.).
With respect to the model formulation encountered in 1.3.1, a correlation with the quan-
tities in play leads to
1. Individual Model
￿ zi;j is the drug concentration for subject i at time ti;j, that is zi;j = C(ti;j)1.3. BASICS OF NON LINEAR MIXED EFFECT METHODS 7
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Figure 1.3: Example of drug concentration proles after oral administration (each color
identies a single subject).
￿ ui is the dose given to subject i a time t = 0, that is ui = Di
￿ pi are the PK parameters (ka;Cl;V ) specic to subject i, i.e. pi = (kai;Cli;Vi)
￿ f(ti;ui;pi) describes how the concentration of the ith subject evolves in time in
a one-compartment model with rst order absorption, i.e.
f(ti;ui;pi) =
Dikai
Vi(kai   Cli
Vi )

e
 
Cli
Vi
ti   e kaiti

2. Population Model
￿ ai =

Gi BWi
T, where Gi and BWi are the gender and the body weight of
subject i respectively8 CHAPTER 1. INTRODUCTION
Figure 1.4: One compartment model with rst order absorption from the gut compartment.
Such model allows to take into account oral administration.
￿ i =

1;i 2;i 3;i
T
i s N(0;
);
 =
2
4
!2
11 !2
12 !2
13
!2
21 !2
22 !2
23
!2
31 !2
32 !2
33
3
5
where diag(
) quanties the varaibaility accross individuals of (ka;Cl;V ), re-
spectively.
￿  =

1 2 3 4
T
￿ The d function is the one that relates (kai;Cli;Vi) to (ai;i;), for example:
kai = 1  e1
Cli = (2 + Gi  3)  e2
Vi = (BWi  4)  e3:
In the pharmacokinetic context the use of exponentials on random eects i is required
becuase of dealing with physiological entities, which are positive by implication. In addi-
tion, in the formulas above, an in
uence of the gender on the clearance and an in
uence
of the body weight on the volume of distribution is assumed.1.4. BASICS OF BAYESIAN ESTIMATION 9
1.4 Basics of Bayesian Estimation
In the branch of estimation theory, Bayesian approach refers to the situation in which the
information available comes from two dierent sources. Dening y as the observed data
and  as the quantity to be estimated (a vector of parameters, a signal, etc.), these two
founts are:
￿ Likelihood: the knowledge on the relationship between y and , denoted as p(yj);
￿ Prior: the probabilistic a priori information on , denoted as p();
thus, both y and  are treated as random variables.
Bayes theorem (equation (1.4)) enables to combine these two probability densities in order
to obtain the so-called posterior density function p(jy):
p(jy) =
p(yj)p()
p(y)
(1.4)
Translating the theorem in practical term: p() represents the prior knowledge we have
on the quantity to be estimated, if such quantity is somehow related to data y, the ob-
servation of y (i.e. p(yj)) changes our expectations on  in p(jy). In other words, by
applying Bayes theorem we are extracting the estimate by way of a compromise between
our knowledge on the quantity to be estimated and what the data is telling us (see Figure
1.5).
It is easy now to deduce the main dierence between Bayesian inference and other ap-
proaches: through Bayes theorem the entire distribution of the parameters of interest can
be estimated, providing a great amount of information. In fact, the use of posterior distri-
bution is indeed wide, both because there are dierent ways to obtain the point-estimator
of the parameter (such as the posterior mean, the posterior median or the posterior mode)
and because it provides the credible intervals, which are a reliable measure (compared to
condence intervals used in frequentist approach) of the uncertainty of an estimate.
In order to be able to evaluate the postierior density function, Bayes theorem of equation
(1.4) can be rewritten, using the \Law of Total Probability", as
p(jy) =
p(yj)p() R
 p(yj)p()d
: (1.5)
The denominator of equation (1.5) is a constant and does not depend on ; hence, in
the intereset of simplifying the formula as much as possible, we may consider
p(jy) / p(yj)p() (1.6)
Unfortunately, only in a few particular cases p(jy) is available in closed form, that is
when the prior and the posterior come from the same family of distributions, and in this10 CHAPTER 1. INTRODUCTION
case the prior is said to be conjugate to the likelihood. Example 1.4.1 shows one of these
cases.
Example 1.4.1. Let us consider a drug to be given for relief of chronic pain whose expe-
rience with similar compounds has suggested that annual response rates between 0.2 and
0.6 could be feasible, then we may interpret this as a distribution with mean = 0.4 and
standard deviation = 0.1. Suppose we now treat n = 20 volunteers with the compund and
observe y = 15 positive responses.
￿ Likelihood. Assuming patients are independent, with common unknown response rate
, leads to a binomial likelihood (Figure 1.5a):
y s Binomial(;n)
p(yjn;) =

n
y

y(1   )n y / y(1   )n y
￿ Prior. A probability distribution which ts with the requests on the response rate is
a Beta distribution (with a=9.2 and b=13.8, see Figure 1.5b):
 s Beta(a;b)
p() =
 (a + b)
 (a) (b)
a 1(1   )b 1 / a 1(1   )b 1
￿ Posterior. Combining the Binomial likelihood and the Beta prior gives the following
posterior distribution
p(jy;n) / p(yj;n)p()
p(jy;n) / y(1   )n ya 1(1   )b 1 = y+a 1(1   )n y+b 1
which is still a Beta dsitribution (with dierent parameters, see Figure 1.5c):
p(jy;n) / Beta(y + a;n   y + b)
In most cases p(jy) is not analitically tractable and we want to obtain the marginal pos-
terior p(ijy) for each i and calculate properties of p(ijy) such as the mean (
R
ip(ijy)di)
and the tail areas (
R 1
T p(ijy)di). Given that evaluating these integrals analitically is im-
possible, numerical integration becomes vital. WinBUGS [6] is a free software that allows
to obtain every p(ijy) and compute integrals on them via Markow Chain Monte Carlo
(MCMC) techniques.1.4. BASICS OF BAYESIAN ESTIMATION 11
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Figure 1.5: Probability density function (up to a multiplicative constant) of: Likelihood (a),
Prior (b) and Posterior (c) dened in example 1.4.1. It may be noticed how the posterior
obtained would be in the middle (a compromise) between the prior and the likelihood.Chapter 2
Materials and Methods
2.1 Preclinical Protocol
2.1.1 Pharmacokinetic Data
The compound (GSK945237) was administered orally twice daily (Bis In Die, i.e. BID)
with approximately 6 hours between doses to nine male and nine female beagle dogs (total
number of individuals=18) at total daily doses of 0, 30, 100 and 300 mg/kg/day (0, 15,
50 and 150 mg/kg/day BID, respectively). Plasma samples were obtained from blood
collected into tubes containing EDTA from drug-treated and placebo-control animals at
the following nominal times: predose, 0.25, 0.5, 1, 3, 6, 6.25, 6.5, 7, 9 and 24 hours after
the rst dose.
Plasma samples were analyzed for GSK945237 using a validated analytical method based
on protein precipitation, followed by HPLC-MS/MS analysis. Using a 50 L aliquot of
dog plasma, the lower limit of quantication (LLQ) for GSK945237 was 0.1 ng/L and the
higher limit of quantication (HLQ) was 50 ng/L.
2.1.2 Pharmacodynamic Data
Four male dogs were given placebo and total daily doses of 30, 100 and 300 mg/kg (15, 50
and 150 mg/kg administered twice daily approximately 6 hours apart) of test article orally
by gavage on separate days, with at least 7 days between each dose, according to a 4x4
latin square crossover paradigm. Dogs were dosed at approximately 9:00 AM on each day
of dosing. ECG waveforms were recorded continuously from 2 hours prior to dosing to 24
hours after dosing and all derived parameters were recorded as 1-minute means.
According to the aim of the analysis and given the enormous amount of data collected
overall, raw QT data was diluted every 2 minutes during the absorption phase (roughly
t<2.5hrs and 6hrs<t<8.3hrs, where t is the time after dosing), every 5 minutes during
the distribution phase (2.3hrs<t<6hrs and 8.3hrs<t<15hrs) and every 15 minutes during
1314 CHAPTER 2. MATERIALS AND METHODS
the elimination phase (t>15hrs). Also, part of the ECG data collected around the dosing
times had to be discarded due to the bad quality of the data caused by an abnormal dogs
excitement.
2.2 Clinical Protocol
2.2.1 Pharmacokinetic-Pharmacodynamic (PK-PD) Data
The study was a rst-time-in-human to investigate the safety, tolerability, and pharmacoki-
netics of escalating single oral doses of GSK945237. The adopted design was a single-blind,
randomized, placebo-controlled, dose-rising study conducted in sequential cohorts. Forty-
ve (45) subjects were enrolled into 6 cohorts. According to a randomization schedule pre-
pared prior to study start, 6 subjects received active drug and 3 subjects received placebo
at each dose level (50mg, 150mg, 400mg, 1000mg, 2000mg and 2600mg). Each subject
participated in one study period and received either GSK945237 or matching placebo.
Following a single oral dose of GSK945237, blood samples for pharmacokinetic analysis
and ECG waveform samples for pharmacodynamic analysis of GSK945237 were collected
over a 60-hour period from groups receiving doses of 50mg, 250mg and 500mg and over
a 120-hour period from groups receiving 1000mg and 1750mg. Bioanalysis of GSK945237
plasma concentrations was conducted using a validated analytical method based on solid
phase extraction followed by HPLC-MS/MS. The lower limit of quantication (LLQ) for
GSK945237 was 10 ng/mL, using a 100 L aliquot of human plasma with a higher limit of
quantication (HLQ) of 5000 ng/mL.
2.3 Pharmacokinetic Modelling
The goal of the pharmacokinetic (PK) modelling in the whole project is to obtain time
matched concentration and QT interval values, since this is required for the assessment
of the pharmacokinetic-pharmacodynamic (PK-PD) relationship. In order to do this, PK
modelling has been performed using non-linear mixed eect techniques (see 1.3.2 for an
example) implemented in NONMEM 7.1.2 [7]. Once identied the best PK model for
GSK945237, the parameter estimates obtained are used to generate simulated concentra-
tion proles with the same sampling time used to collect QT measurements.
Since in human data QT measurements and concentration measurements were collected
simultaneously, the PK step was executed only for conscious dogs data, where the QT
sampling time is usually low (30 sec/1 min) and therefore an equal PK sampling time is
not achievable for obvious reasons.
Firstly, provided that the drug administration was oral, a model with rst order absorption
had to be taken into account. Secondly, the BID way of administration made it dicult to
describe the data after the second daily dose since the dogs had free access to food between2.4. PK-PD MODELING OF THE QT INTERVAL 15
the two daily doses, determining the appearaence of a food eect in the data. Finally, the
NONMEM analysis led to the conclusion that a one compartment model with rst order
absorption (Fig.1.4) best decribes the kinetic of the analyzed drug.
2.3.1 NONMEM Model Formulation
The mandatory parameters for a one compartment model with rst order absorption are:
Rate of Absorption (Ka), Clearance (Cl) and Volume of Distribution (V ). Bioavailability
(F) was also included in the model in order to describe the food eect.
After a covariate analysis, it emerged that the Clearance and the Volume of Distribution
are aected by the gender and the body weight of the individuals, respectively.
The detailed model formulation is (t represents the time variable):
FECl =

1 if GENDER=M
2 if GENDER=F
=) Cl = FECl  e1
V = WT  3  e2
FEKa =

4 if First Daily Dose (FDD)
5 if Second Daily Dose (SDD)
=) Ka = FEKa  e3 (2.1)
F =
8
> > <
> > :
6 if DOSE=30 mg/kg and DOSE=SDD
7 if DOSE=300 mg/kg and DOSE=FDD
8 if DOSE=300 mg/kg and DOSE=SDD
1 otherwise
(2.2)
The residual error model that has produced the lowest objective function value is a
mixed (proportional and addittive) one:
Y = f(;;t)  (1 + 1) + 2 (2.3)
where Y is the observed concentration, f(;;t) the predicted concentration, 1 s
N(0;2
1) and 2 s N(0;2
2).
2.4 PK-PD Modeling of the QT interval
The aim of this section is to dene a mathematical model able to decribe the QT interval.
Since there are dierent sources contributing on QT variation, each of them is explored.16 CHAPTER 2. MATERIALS AND METHODS
2.4.1 Modelling the Drug Eect
Pharmacodynamics can be dened as the relationship between the drug concentration
in the plasma and the pharmacological eect. In order to be able to characterize this
relationship and quantify the drug response, various mathematical models are available
[8]. Among those, the one that has been implemented is a linear concentration-eect
model (Figure 2.1)
E = E0 + S  C (2.4)
where E indicates the drug eect, E0 the baseline eect, C the plasmatic concentration of
the drug and S the slope parameter.
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Figure 2.1: Observed eect (dots) versus concentration described by a linear model (solid
line).
Despite an ordinary Emax model (Figure 2.2)
E = E0 +
Emax  C
EC50  C
(2.5)
(where EC50 denotes the plasma concentration corresponding to the half-maximal dif-
ference between baseline E0 and the maximal eect Emax) might be more physiologically
plausible as it takes into account the maximum eect, the range of concentration values
involved in QT studies does not determine any saturation eects, allowing the use of a2.4. PK-PD MODELING OF THE QT INTERVAL 17
linear model.
In the context of QT variation, equation (2.4) can be rewritten as
QTDE = Slope  C (2.6)
where QTDE represents the variation of the QT interval due to the drug eect and
the unit of measurement of the Slope will be [ms=concentration]. The baseline eect E0
will be consider in section 2.4.2.
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Figure 2.2: Observed eect (dots) versus concentration described by an Emax model (solid
line).
2.4.2 Modelling the QT-RR Relationship
It has been already mentioned that the QT interval depends on the RR one, but how are
they related? Since 1920 when two pioneering article appeared [9],[10], many eorts have
been made to nd a formula that provides the ideal correction such that the corrected QT
interval is indipendent of the RR interval.
The most used formulas so far are the so-called Bazett correction [9]
QTcB = QT  RR 0:5 (2.7)18 CHAPTER 2. MATERIALS AND METHODS
and Friedericia correction [10]
QTcF = QT  RR 0:33 (2.8)
where QT is in [ms] and RR is in [s] (there is no a scientic reason why RR and QT
have two dierent measurement units in these formulas, on the contrary, it came out from
empirical evidence). Figure 2.3 compares the two formulas using as an example a pooled
dataset comprising QT-RR measurements from 45 individuals. Between the two formulas,
that of Friedericia (Figure 2.3b) performs on avarage quite well (the loess smoother is al-
most horizontal), while Bazett formula (Figure 2.3a) determines an over-correction.
Despite the good behaviour of Friedericia's formula, equations (2.7) and (2.8) have been
derived from population data, and the large dierence between these formulae suggests
that the QT/RR relationship has not been found reproducible from study to study. It is
therefore unreasonable to expect that a general formula could satisfy the QT/RR relation-
ship for the data of a given study, namely, individuals show dierent QT/RR relationships.
Keeping the same template of equations (2.7) and (2.8), the QTc baseline interval (QTc0)
can be described as
QTc0 = QT0  RR  (2.9)
where QT0 is the measured QT baseline interval. Now, given that the aim is to describe
the QT interval, equation (2.9) has to be rewritten as
QT0 = QTc0  RR (2.10)
A population approach makes possible to estimate every individual correction factor i
obtaining a population parameter  denoting the QT correction factor for the population
recruited in the specic study. Furthermore, QT0 in equation (2.10) plays the role of the
baseline eect E0 introduced in equation (2.4) which was lacking in equation (2.6).
2.4.3 Modelling the Circadian Rhythm
As mentioned in section 1.1, the QT interval depends on several factors. Obviuosly, trying
to build a model able to describe each of them would be too complex as well as without
any pharmacological interest. Amongst the elements in
uencing the QT, apart from the
aforementioned RR interval and drug eect, the circadian rythm is one of the most sizable
(see Figure 2.4).
In general, the statistical signicance of the circadian rythmicity can be documented
by the cosinor analysis [11], [12]. This method characterizes a rhythm by the parameters
of a tted cosine function
QTcirc = A  cos

2
24
(tc   )

(2.11)2.4. PK-PD MODELING OF THE QT INTERVAL 19
where QTcirc denotes the variation in milliseconds of the QT interval due to the
circadian rythm, A [ms] and  [hr] are its amplitude and phase respectively and tc is the
clock time.
The ability to estimate the crircadian component is limited by the number of QT interval
measurements available and their spread over the day. In fact, since the precision of QT
data is low, a large number of observations is needed to extract a signal coming from the
circadian ryhtm.
Concluding, the nal model may be obtained by gathering each of the single contributes
described so far, i.e. the drug eect (equation (2.6)), the QT/RR relationship (equation
(2.10)) and the circadian rythm (equation (2.11)), that is, QT = QT0+QTcirc+QTDE,
which leads to
QT = QTc0  RR + A  cos

2
24
(tc   )

+ Slope  C (2.12)
2.4.4 WinBUGS Model Formulation
The PK-PD model of equation (2.12) has been implemented in WinBUGS via a hierarchical
model which allows to take into account dierent sources of variability, as well as prior
distributions (Figure 2.5).
The detalied formulation is the following (hereafter: i = 1;:::;N individuals, k = 1;:::;P
occasions and j = 1;:::;M time samples)
QTi;k;j = fk;j(pi) + j (2.13)
where j is the measurement error, at time j, assumed normally distributed (j s
N(0;2
)) and
fk;j(pi) = QTc0i;k  RR
i
i;j + Ai  cos

2
24
(tcj   i)

+ Slopei  Ci;j (2.14)
is the direct translation of equation (2.12).
Carrying on with the fromulation, pi is a vector of individual parameters
pi =

p1;i p2;i p3;i p4;i p5;i
T
which will be used to derive the actual parameters appearing in the model and follows
a multivariate normal distribution (MVN)
pi s MVN(;
)
where
 =

1 2 3 4 5
T20 CHAPTER 2. MATERIALS AND METHODS
represents the vector of the xed-eects and

 =
2
6
6 6
6
4
!2
11 !2
12 !2
13 !2
14 !2
15
!2
21 !2
22 !2
23 !2
24 !2
25
!2
31 !2
32 !2
33 !2
34 !2
35
!2
41 !2
42 !2
43 !2
44 !2
45
!2
51 !2
52 !2
53 !2
54 !2
55
3
7 7
7 7
5
depicts the random-eect component, i.e. the Between Subject Variabilty (BSV) of the
parameters.
The parameters of equation (2.14) are expressed as follows:
QTc0i;k = epi;1+k (2.15)
where the variable k is normally distributed around 0 with variance 2
 (i.e. k s
N(0;2
)) and has been introduced in order to take into account the variability of the
baseline QTc across study periods (the baseline QTc varies from day to day). Such a
source of variabilty is called Inter-Occasion Variability (IOV). Furthermore, as the QTc0 is
a physiological parameter and therefore can not be negative, we make sure it will assume
only positive values by taking the exponent of pi;1 + k.
i = epi;2
It has already been described how the RR aects the QT interval (see section 2.4.2).
In particular, from equation (2.10), we know that the parameter  has to be positive. This
is the reason why the exponent of pi;2 was considered.
Ai = epi;3
i = epi;4
A and  are the model parameters used to describe the circadian component of the QT
interval. Theoretically, the sign of these two parameters is arbitrary, therefore no positive
constrains should be adopted. However, from a practical point of view, i.e. in order to
narrow the optim parameters searching eld, exponential terms were considered, forcing A
and  to be positive. With the aim of being able to assert that this choice does not aect
the parameters' estimate, a model run with a negative constrain on A was performed (i.e.
Ai =  epi;3). Results shown in Figure 2.6 enable to draw the conclusion that the model
recognizes the fact that the amplitude cannot be positive, and in consequence shifts the
phase  to a value 12Hr greater than the previous one, thereby obtaining the same overall
estimate of the cyrcadian rhythm component.
Slopei = 10 5  pi;5 (2.16)2.4. PK-PD MODELING OF THE QT INTERVAL 21
The formulation of Slope showed above contains a multiplication by 10 5, whose goal
comes from numerical issues. Since Slope parameter is known to be low, equation (2.16)
ensures that pi;5 will be a reasonable high number, supporting the algorithm in nding a
solution.
Priors Choice The selection of a prior for a given parameter is, in principle, subjective:
it might be elicited from experts, it might be based on historical data (e.g. a previous
study) or it might be convenient to assume a vague, non-informative prior.
As to priors on 2
 and 2
, a Jerey's prior on the inverse of these two quantities is a
standard choice if no a-priori information is present on them (non-informative prior):
1
2

s Gamma(;)
1
2

s Gamma(;)
where  is an arbitrary small number (usually  = 0:001).
Concerning the parameters  and 
, the choice was also for non-informative priors in order
to do not bias the estimation too much. In particular, the priors were specied as:
 s MVN(;)
where
 =
2
6 6
6 6
4
0
0
0
0
0
3
7 7
7 7
5
; = 104 
2
6 6
6 6
4
1 0 0 0 0
0 1 0 0 0
0 0 1 0 0
0 0 0 1 0
0 0 0 0 1
3
7 7
7 7
5
and

 1 s Wp(R;5)
where Wp(R;) indicates a Wishart distribution with scale matrix R and degrees of
freedom  and it is a common choice for prior of the inverse covariance-matrix (i.e. 
 1)
of a multivariate-normal random-vector (i.e. ) since it is a conjugate prior for it [13]. To
represent vague prior knowledge,  was set small as possible (i.e. 5, the rank of ). Finally,
the scale matrix was specied as
R =
2
6 6
6
6
4
1 0 0 0 0
0 1 0 0 0
0 0 1 0 0
0 0 0 1 0
0 0 0 0 1
3
7
7 7
7
5
;22 CHAPTER 2. MATERIALS AND METHODS
an arbitrary, as well as common, option given that the choice of R has little eect on
the posterior estimate of 
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Figure 2.3: Comparision between the RR correction formulas of equations (2.7) and (2.8):
(a) Bazett correction and (b) Friedericia correction. The dots represent the QTc measure-
ments. The loess smoother (solid line) shows a better performance for Fridericia correction.24 CHAPTER 2. MATERIALS AND METHODS
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Figure 2.4: QT intervals (circles) measured in placebo groups vs clock time. The solid line
is a loess smoother showing a circadian variation in the QT.2.4. PK-PD MODELING OF THE QT INTERVAL 25
Figure 2.5: Graph of the hierarchical model used for the PK-PD analysis. The dierent
levels are, from lower to higher: Prios level, Population level, Individual level, Occasion
level and Measurement level.26 CHAPTER 2. MATERIALS AND METHODS
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Results
3.1 Pharmacokinetic Analysis
3.1.1 Preclinical Data
In this section, results from the preclinical PK model of GSK945237 (described in section
2.3.1) will be presented and discussed. The outcomes will be interpreted through both a
numerical and graphical point of view. All the estimates that are going to be documented
were obtained in NONMEM adopting the pre-implemented Maximum Likelihood estima-
tion algorithm called First Order Conditional Estimation (FOCE) with interaction.
A fair diagnostic plot to see how the model works at rst glance is the so called Goodness
of Fit (GOF) plot for population prediction (Figure 3.1). The population GOF plot aims
to show the overall behaviour of the model, and the key point to interpret it is that the
closer the black dots are to the unity line the better the prediction is, since this is proof
of a good correlation between observed and predicted concentrations. The plot reveals a
diculty in getting the higher concentration values as there is a slight shift of the dots un-
der the unity line for measured concentrations in between 23-30 ng/L. Nevertheless, given
the small number of indivduals involved in the study (18), the model may be accepted
and subjected to further examination. Figure 3.2 illustrates the GOF plot for individual
predicted concentrations, which are obtained by way of a Maximum a Posteriori (MAP)
Bayesian estimatation of the indivdual PK parameters using the population estimates as
priors (this step is automatically done by NONMEM). In this case the correlation between
predictions and observations is higher than in the population GOF, which is what one
would expect since there is an individual prediction for every subject.
The residuals analysis is an alternative way to evaluate the goodness of a model. A residual
is dened as the dierence between the observed measure and the model prediction, there-
fore the lower the residuals are the better the prediction is; on the other hand, weighted
residuals are residuals scaled by a certain weight parameter (for example the variance of
the measurement error, if we have information on it) that quanties the condence we have
2728 CHAPTER 3. RESULTS
on a certain sample. Under certain statistical assumptions, in order to assess the goodness
of the prediction, two particular features of the weighted residuals have to be checked: cor-
relation (the more they are uncorrelated the better the t is) and amplitude (they should
be distributed around -1 and 1). Outcomes from such analysis are showed in Figure 3.3,
and it can be seen the performance of the model is overall good, except for a sistematic
bias in the last sample. Given the goal of the PK step though, since we are interested in
higher concentrations and the model lacks on the last sample which is associated with a
very low concentration value, this 
aw may be neglected.
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Figure 3.1: Goodness of Fit plot for the population preditced vs. observed drug concen-
tration (the solid line depicts the unity line).
A more accurate diagnostic tool is represented by the Visual Predictive Check (VPC),
which is mainly used to support the appropriateness of a model. The VPC is constructed
from stochastic simulations of the model, therefore all the model components contribute
and it can help in diagnosing both structural and stochastic contributions. In Figure 3.4 is
portrayed the outcome from 1000 model's simulations where the 25th and 75th percentiles
have been chosen due to the small size of the dataset [15]. The plot displays the capacity
of the model to express the variabilty that exists among individuals, where the accuracy in
doing that is conrmed by the fact that the measurements lying further the two percentiles
are around the 25% of the whole dataset (Table 3.1).
Now that the goodness of the model has been established, all the parameter estimates
may be explored.3.1. PHARMACOKINETIC ANALYSIS 29
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Figure 3.2: Goodness of Fit plot for the individual preditced vs. observed drug concentra-
tion (the solid line depicts the unity line).
Percentage of data above the Percentage of data beneath the
75th percentile 25th percentile
28.8% 24.7%
Table 3.1
Table 3.2 contains the estimates (with their coecient of variations) of the xed eects
of the model. Referring to Figure 3.5 and the values obtained for 4 and 5, it should be
appear clear why the Ka has been formulated as in equation (2.1): mostly due to the food
eect, the rate of absorption of the rst daily dose is rather higher than the one in the
second dose. Also, as it may seen from the large variability in the second peak between
Figures 3.5a, 3.5b and 3.5c, the fact that dogs were fed between the two daily doses has
an in
uence in the maximum concentration of the second daily dose as well, depending on
the amount of drug administered. In the interest of making the model sensitive to such
eect, three dierent bioavailabilities for the three dierent dose regimens (30, 100 and
300 mg/kg) were taken into account (equation (2.2)), where the \full bioavailabilty" (i.e.
F = 1) was assumed to be the one on the rst daily dose and on the 100 mg/kg dosing
regimen.30 CHAPTER 3. RESULTS
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Figure 3.3: Population weighted residuals (a) and individual weighted residuals (b).3.1. PHARMACOKINETIC ANALYSIS 31
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Figure 3.4: Visual Predictive Check of the PK model (1000 simulations). Dots: observed
concentrations, solid line: median of the 1000 simulated proles, dashed lines: 25th and
75th percentile of the 1000 simulated proles.
1 2 3 4 5 6 7 8  L
hr

[L]
 1
hr

unitless
Value 6.34 4.51 3.45 8.59 0.789 0.609 0.44 0.78
CV (%) 10.1 8.8 7.1 20.8 23.4 9.7 11 12.5
Table 3.2: Estimates of the population mean parameters along with their precisions (ex-
pressed via percentage coecient of variation) of the PK model.
Finally, the estimates of the random eects are proposed. As discussed in section 1.3.1,
in the rst place the random eects are associated with two sources of variability: Between
Subject (Table 3.3) and Intra (Within) Subject (Table 3.5).
The estimates of the BSV in Table 3.3 are depicted by means of coecients of variation, that
is BSVn = !n
n , where !n is the true enitity that expresses the BSV of the nth (n = 1;2;3)
parameter, but it is divided by the population mean in the interest of having a relative
measure of the variability of that particular parameter. A further indicator of the goodness
of the BSV estimates is the result of an hypothesis test on the values of n, assuming as
null hypothesis that n has mean zero (see equation (1.3)). Table 3.4 summarizes the out-
comes of this test, showing p-values that allow to accept the null hypothesis, i.e. all the n
have mean zero, giving an additional evidence of the appropriateness of the proposed model.
Regarding the Intra Subject Variability (ISV) estimates of Table 3.5, the proportional32 CHAPTER 3. RESULTS
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Figure 3.5: Obsereved concentrations (dots), population prediction (dashed line) and indi-
vidual prediction (solid line) obtained from the PK analysis. Indivduals showed come from
the three dosing groups: (a) 30 mg/kg/day, (b) 100 mg/kg/day and (c) 300 mg/kg/day.3.2. PHARMACODYNAMIC ANALYSIS 33
Ka Cl V
FDD SDD M F
BSV (%) 8.0 86.8 4.2 5.9 4.7
CV (%) 28.2 28.2 69.7 69.7 49.7
Table 3.3: Estimates of the Between Subject Variability (expressed via percentage co-
ecient of variation) along with their precisions (expressed via percentage coecient of
variation) of the PK parameters.
1 2 3
Sample Average 1:24  10 3  9:13  10 3  1:37  10 3
p-value 0.98 0.76 0.93
Table 3.4: Sample averages accross individuals of the random eects. The P-values come
from a hypothesis test where the null hypothesis is that the mean of n is zero.
term of equation (2.3) was evaluated as 1%, whilst the addittive term as 2.
Proportional(1) Addittive(2)
ISV 23.4% 0.144 ms
CV (%) 20.3 33.2
Table 3.5: Estimates of the Intra-Subject Variability (ISV) along with their precisions
(expressed via percentage coecient of variation) described in equation (2.3).
3.2 Pharmacodynamic Analysis
As it was already mentioned in section 1.4, the amount of information that Bayesian
inference can provide is considerable and will be discussed in sections 3.2.2 and 3.2.3.
Further, performing such analysis in WinBUGS entails the necessity of checking whether
the dierent runs converged correctly (section 3.2.1).
3.2.1 MCMC Convergence Check
WinBUGS analysis is based on MCMC methods, a class of algorithms for sampling from
probability distributions based on constructing a Markov chain that has the desired dis-
tribution as its equilibrium distribution (see [6] for details). An example of two Markov
chains is shown in Figure 3.6, and a rst step to assess the convergence is to visually check
that the two chains are uncorrelated and overlap, which is the case for Figure 3.6.34 CHAPTER 3. RESULTS
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Figure 3.6: Standard output of a WinBUGS run: two Markov chains of QTc0 parameter
in humans.
A problem with MCMC methods is that convergence cannot always be diagnosed as
clearly as in optimization methods. Indeed, there are several diagnostic tools that have
been proposed since GIBBS sampling became popular in Bayesian inference ([16], [17], [18],
[19]) and it may be very dicult to satisfy all these criterions. In order to do not make the
convergence check step too complex and lenghty, only the Gelman-Rubin diagnostic [17]
will be performed, along with the assessment of low Monte Carlo (MC) errors, essential for
precise estimation of the posterior distribution [20].
Gelman and Rubin method constits in dierent steps. Firstly, to evaluate the within chain
variance W (hereafter j = 1;:::;m chains, i = 1;:::;n iterations and ij is the ith sample of
the jth chain of an arbitrary unknown parameter ) as
W =
1
m
m X
j=1
s2
j
where s2
j is the sample variance of  in chain j:
s2
j =
1
n   1
n X
i=1
(ij    j)2
and  j is the sample mean of  in chain j:
 j =
1
n
n X
i=1
ij:3.2. PHARMACODYNAMIC ANALYSIS 35
Secondly, to evaluate the between chain variance B as
B =
n
m   1
m X
j=1

 j     
2
where    is the sample mean  between chains:
   =
1
m
m X
j=1
 j:
We can then estimate the variance of the stationary distribution as a weighted average
of W and B, i.e.
^ 2
 = (1  
1
n
)W +
1
n
B;
that is used to dene the nal parameter of interest, named Potential Scale Reduction
Factor (PRF)
PRF =
s
^ 2

W
(3.1)
which should be as close to 1 as possible to state that the chains converged.
PRF values obtained from Markov chains of parameters of interest in both preclinical
and clinical data are presented in Table 3.6. The same table contains also index  of
equation (3.2), which helps to assess the convergence achievement in terms of MC error;
particularly,  should be less than 5%.
 =
MCerror
SDestimate
 100 (3.2)
Table 3.6 suggests convergence of parameters A and  in clinical data has not been
totally achieved, as indicated by a PRF > 1:5 and a  > 5%. Nevertheless, increasing the
number of iterations does not solve the problem and the reason of a bad convergence most
likely lays in the low amount of QT samples (8) collected from each patients trhougout the
day. Moreover, in both species chains related to the drug eect parameter (i.e. Slope) also
present convergence issues, and this might be due to the fact that the parameter is moslty
zero (i.e. the drug eect is moslty absent) therefore chains struggle to overlap and follow
a straight pattern since sample values range in a very limited interval (see Figure 3.7).36 CHAPTER 3. RESULTS
PRF
QTc0  A  Slope
DOG 1.00 1.01 1.05 1.14 2.21
HUMAN 1.00 1.48 2.95 1.89 1.17
 (%)
DOG 0.92 0.98 1.29 2.65 6.11
HUMAN 1.49 4.76 5.57 5.17 5.69
Table 3.6: Potential Scale Reduction Factors and  indices obtained after running the
WinBUGS model for both dog and human data.
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Figure 3.7: Markov chains of Slope parameter in preclinical data.
3.2.2 Preclinical Data
A thorough Bayesian analysis allows to estimate the full posterior distributions of the
investigated parameters, enabling to extrapolate quantitative information by means of
computing precentiles and means of such distributions. In regard to the PKPD model of
equation (2.12), Figure 3.8 illustrates the probabilty density function (pdf ) of parameters
QTc0, , A,  and Slope in conscious dog data. The shapes of these distributions supply
a qualitative idea on the range of values assumed by the parameters. Also, the shape acts
as an additional option of convergence inspection; the pdf, in fact, is an alternative way to
represent the run Markov chains for that parameter, thereby it should not contain peaks
and troughs since they would be evidence of lack of overlapping between chains as well as
correlation within chain.3.2. PHARMACODYNAMIC ANALYSIS 37
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Figure 3.8: Posterior distributions of the PKPD model parameters in dog data: QTc0 (a),
 (b), A (c),  (d) and Slope (e).38 CHAPTER 3. RESULTS
Posteriors obtained elucidates a successfull conclusion of the estimation step. Nonethe-
less, Figure 3.8e conrms what Table 3.6 had previoulsy told, i.e. a perfect convergence of
Slope Markov chains is dicult to achieve as elicited from the irregular shape of the pdf.
QTc0  A  Slope
[ms] unitless [ms] [hr] [ ms
nM]
10% Credible Interval 251.0 0.251 6.34 12.24 -1.210 5
Mean 255.3 0.304 8.77 16.48 1.610 5
90% Credible Interval 259.7 0.365 11.93 22.68 4.510 5
CV (%) 1.4 14.9 28.1 28.2 136.6
Table 3.7: Mean, 80% credible intervals and precision (expressed as percentage coecient
of variation) of the population parameters of the PKPD model of equation (2.12) for dog
data.
A statistical analysis on the posteriors leads to results in Table 3.7, where the parameter
estimates are expressed in terms of posteriors' mean (i.e. the minimum mean square error
(MMSE) estimator). Along with the MMSE estimator there are the 80% credible intervals
and the precision of the estimates expressed as percent coecient of variation.
Once again, the low precision on Slope estimate (136.6%) is an indicator of the problems
arose in nding a complete convergence of the Markov chains for such parameter. An other
interesting consideration that can be done by looking at Table 3.7 concerns the negative
10% credible interval of Slope, which stresses the fact that the drug eect lays around zero
and therefore supports the conclusion that no drug induced QT prolongation takes place
in dog.
BSV IOV ISV
QTc0  A  Slope? QTc0 
% % % %
 ms
nM

[ms] [ms]
10% Credible Interval 41.8 27.7 30.7 26.7 2.010 5 10.71 9.26
Mean 98.6 41.7 48.6 46.4 3.810 5 13.45 9.42
90% Credible Interval 403.1 74.8 96.0 91.2 7.210 5 17.50 9.59
CV (%) 166.6 153.2 229.1 177.1 164.9 43.0 1.4
?
Because of Slope BSV 10% credible interval is negative, Slope BSV has not been represented via coecient of variation
since such measure is not denable for negative quantities.
Table 3.8: Mean, 80% credible intervals and precision (expressed as percentage coecient
of variation) of the random eects of the PKPD model of equation (2.12) for dog data.
Unlike standard ways of estimation, Basyesian estimation handles every enitity as a
distribution, hence posteriors and credible intervals may be obtained also for parameters3.2. PHARMACODYNAMIC ANALYSIS 39
conveying variability in the model, i.e. 
 (Between Subject Variability), 2
 (Inter Occasion
Variability) and 2
 (Intra Subject Variability). Table 3.8 contains MMSE estimator and
80% credible interval of parameters that quantify each source of variability. It may be
noticed that CV values in BSV are all above 100%, re
ecting an inaccurate estimate on
how much the parameters vary amongst individuals. Such weakness in detecting reliable
measures of the BSV is due to the very low number of dogs (4) enrolled in the PD study.
3.2.3 Clinical Data
Since there is no dierence in the PKPD model between species, the same kind of dissection
performed for preclinical data in section 3.2.2 will be presented. Starting from the estimated
posterior distributions, Figure 3.9 shows proles of A and  are too wavy to conclude
Markov chains for those parameters have fully convegred (Figure 3.9c and 3.9d), reinforcing
the hypothesis made in section 3.2.1 that the number of QT measurements collected per
day is too little to be able to extrapolate information on the cyrcadian rhythm.
QTc0  A  Slope
[ms] unitless [ms] [hr] [ ms
nM]
10% Credible Interval 389.7 0.201 2.77 5.97 1.610 6
Mean 392.9 0.239 3.44 7.33 4.210 6
90% Credible Interval 396.1 0.275 4.09 8.59 7.110 6
CV (%) 0.6 12.2 23.0 27.1 52.9
Table 3.9: Mean, 80% credible intervals and precision (expressed as percentage coecient
of variation) of the population parameters of the PKPD model of equation (2.12) for clinical
data.
BSV IOV ISV
QTc0  A  Slope QTc0 
% [ms]
10% Credible Interval 30.1 27.9 29.0 31.9 61.8 15.2 12.66
Mean 44.2 38.9 44.9 63.2 113.2 17.5 13.27
90% Credible Interval 81.5 58.1 69.2 104.4 292.0 20.3 13.94
CV (%) 47.7 29.4 35.0 45.6 37.8 23.2 3.8
Table 3.10: Mean, 80% credible intervals and precision (expressed as percentage coecient
of variation) of the random eects of the PKPD model of equation (2.12) for clinical data.
With regards to the MMSE estimates of the model's parameters, it has to be mentioned
that results from human data lead to the same conclusions in terms of drug eect. Indeed,40 CHAPTER 3. RESULTS
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Figure 3.9: Posterior distributions of the PKPD model parameters in human data: QTc0
(a),  (b), A (c),  (d) and Slope (e).3.2. PHARMACODYNAMIC ANALYSIS 41
as reported in Table 3.9, the Slope estimate is again (approximately) zero. Further, Table
3.10 conrms that with a reasonable number of individuals (45) estimates of BSV are
suciently accurate (CVs are less than 50%). Nevertheless, because of the MMSE estimate
of Slope is close to zero, the estimated BSV of this parameter is quite high; however, since
it can be deduced the in
uence of drug eect in observed data is absent, there is no interest
in the knolwedge of how Slope parameter varies among individuals.Chapter 4
Conclusions
Concerning the assessment of risky QTc increases, according to regulatory guidelines [4] a
threshold of 10 msec was used to explore the probability of QTc interval prolongation at
the relevant therapeutic range. In particular, Table 4.1 enables to infer GSK945237 does
not prolong QTc interval in either humans or dogs since the concentration needed to have
a 50% probability of a QTc prolongation grater than 10 msec is approximately hundred
times bigger than the predicted Cmax.
PC?
50 Cmax
[nM] [nM]
DOG 3500000 62936.18
HUMAN 4200000 13096.86
?
concentration associated with a P(QTc increase  10 msec) = 50%
Table 4.1: PC50 estimates and predicted Cmax in both preclinical and clinical data.
These results diered from typically reported results in telemetered dogs, which are
often based on non-parametric methods and statistical summaries of the data; yet, un-
like traditional, data-driven experiments whose outcomes are often vague and ambigous,
a model based approach provides a robust method to properly evaluate cardiovascular
safety studies, allowing to advance clear and dene conclusions. Moreover, the 
exibility
of the proposed approach, characterised by the usage of a Bayesian framework, eases and
optimizes the interpretation of the results, as proven by the opportunity of obtaining the
probability of a QTc prolongation greater than 10 msec (Figure 4.1). In fact, the assess-
ment of a probability measure rather than a yes or no answer to the question: \is the
QTc prolongation provoked by the drug under investigation matter of concern for further
development of the molecule?" gives considerable advantages in a decision analysis context.
4344 CHAPTER 4. CONCLUSIONS
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Figure 4.1: Curves showing the relationship between concentration and the probability of
a QTc increase grater than 10 msec in dogs (gray line) and humans (black line).
Although no QTc-prolonging eects were observed, results illustrate the value of a quan-
titative approach to characterise drug eects in early drug development. Furthermore, the
analysis reconrms that accurate interpretation of pre-clinical ndings requires suitable
pharmacokinetic sampling and some understanding of expected therapeutic exposure.
In the context of translational pharmacology, the proposed model showed it is able to
predict both human and dog data (see Figure 4.2) making its use suitable for interspecies
scaling of QT interval prolongation. For this purpose, performing the presented analysis for
an adeqaute number of compounds known to have QT prolonging eects may give essential
information on the relationship of such drug eect between humans and dogs. In other
words, estimation of Slope parameter in several drugs and in both species would allow to
nd the existing correlation of that parameter between human and dogs, bridging the gap
between the two species and supporting decision making analysis at the very beginning of
the development of a new compund.45
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Figure 4.2: Individual goodness of t plot of the PKPD model for both preclinical (gray
dots) and clinical (black dots) data; the solid line represents the unity line. The model is
capable to predict both dog and human QT interval.Bibliography
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